NSCLC (Issue 2) | Special Reports

Crizotinib Resistance in ALK-Positive Lung Cancer

February 27, 2014

Clinical Articles

Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses resistance to crizotinib in patients with ALK-positive lung cancer

Clinical Update: ALK-Positive NSCLC

February 27, 2014

Clinical Articles

NSCLC that is positive for ALK, a receptor tyrosine kinase (RTK), typifies a phenomenon termed “oncogene addiction,” in which tumor cells depend on a single causative pathway or protein for their growth and survival.

PD-L1 as a Biomarker for Immunotherapy Agents in Lung Cancer

February 27, 2014

Clinical Articles

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses PD-L1 as a potential biomarker for immunotherapy agents for patients with lung cancer.

Treating Older Patients With NSCLC

February 27, 2014

Clinical Articles

Chandra P. Belani, MD, Deputy Director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses treating older patients who have non-small cell lung cancer

Frontline Treatment Considerations in Non-Small Cell Lung Cancer

February 26, 2014

Clinical Articles

Although the current standard of care for advanced NSCLC remains platinum doublet chemotherapy, recent evidence suggests that most newly diagnosed patients may be candidates for targeted therapy as firstline treatment.